Company Encyclopedia
View More
name
LEE'S PHARM
00950.HK
Lee's Pharmaceutical Holdings Limited, an investment holding company, develops, manufactures, markets, and sells pharmaceutical products in the People's Republic of China, Hong Kong, and internationally. It focuses on various disease areas, such as cardiovascular, woman’s health, pediatrics, rare diseases, oncology, dermatology, and obstetrics. It operates in Proprietary and Generic Products; and Licensed-In Products segments. The Proprietary and Generic Products segment manufactures and sells Nadroparin Calcium injection and Livaracine to treat blood clots and deep vein thrombosis; Yallaferon for viral infection; Slounase for hemostasis; Socazolimab Injection for Recurrent or metastatic cervical cancer; Treprostinil injection for pulmonary arterial hypertension; fondaparinux sodium injection for deep vein thrombosis; and Sodium Phenylbutyrate Granules to treat urea cycle disorders; Apremilast Tablets for Plaque psoriasis; and Azilsartan Tablets for hypertension.
1.450 T
00950.HKMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
B
PharmaceuticalsIndustry
Industry Ranking15/48
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreC
    • ROE5.35%C
    • Profit Margin6.81%B
    • Gross Margin51.82%B
  • Growth ScoreB
    • Revenue YoY19.80%B
    • Net Profit YoY55.10%B
    • Total Assets YoY17.56%A
    • Net Assets YoY12.05%B
  • Cash ScoreB
    • Cash Flow Margin1468.67%B
    • OCF YoY19.80%B
  • Operating ScoreC
    • Turnover0.52C
  • Debt ScoreB
    • Gearing Ratio39.14%B

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    LEE'S PHARM donated 200,000 yuan to assist residents of Hongfu Garden and support related rescue efforts

    LEE'S PHARM expressed deep condolences for the serious fire at Tai Po Hong Fuk Court, which resulted in multiple casualties and many residents left homeless and in urgent need of assistance. The group has donated HKD 200,000 to the "Tai Po Hong Fuk Court Relief Fund" established by the Hong Kong SAR government to assist the residents of Hong Fuk Court and support related rescue efforts. The group also extends its highest respect to the firefighters, medical personnel, and volunteers who worked tirelessly and bravely in the disaster relief efforts, thanking them for their selfless dedication and commitment

    AASTOCKS·
    HK
    00950
    -0.59%
    AASTOCKS·
    HK
    00950
    -0.59%

    LEE'S PHARM granted a total of 1.764 million stock options

    According to a notice from LEE'S PHARM, on October 15, 2025, the company will grant stock options (the "Options") to several eligible participants (the "Grantees") under the stock option plan adopted on May 19, 2022. These options can subscribe for a total of 1.764 million shares of the company's ordinary shares

    Zhitong·
    HK
    00950
    -0.59%
    Zhitong·
    HK
    00950
    -0.59%

    Understanding the Market | LEE'S PHARM rose over 27% in the afternoon as the application for the new indication of Socazoli monoclonal antibody was approved. Institutions are focusing on the palliative care track

    LEE'S PHARM's stock price rose over 27% in the afternoon, and as of the time of writing, it has increased by 20.9%, reaching HKD 2.43, with a trading volume of HKD 44.9021 million. The company's interim results show a revenue of HKD 695 million, a year-on-year increase of 5.5%. The new indication application for Socazolimab submitted by its subsidiary has been approved. Dongxing Securities pointed out that the quality of life for cancer patients is a key focus, and LEE'S PHARM's AZ003 can effectively control cancer pain, which is expected to become an investment focus in the future

    Zhitong·
    HK
    00950
    -0.59%
    Zhitong·
    HK
    00950
    -0.59%

    Hong Kong Stock Movement: LEE'S PHARM surged 22.89%

    LEE'S PHARM surged 22.89%; CSPC Pharmaceutical Group rose 3.00%, with a transaction volume of HKD 793 million; China National Pharmaceutical Group increased by 1.62%, with a transaction volume of HKD 447 million; Fosun Pharma rose 5.58%, with a transaction volume of HKD 314 million; Heng Rui Medicine increased by 1.68%, with a market value of HKD 560.8 billion

    HK Stock Movers Tracker·
    HK
    00950
    -0.59%
    HK Stock Movers Tracker·
    HK
    00950
    -0.59%

    Hong Kong stock movement: LEE'S PHARM rises 15.42%

    LEE'S PHARM rose 15.42%; CSPC Pharmaceutical Group rose 2.80%, with a transaction volume of HKD 755 million; China Biologic Products Holdings rose 1.27%, with a transaction volume of HKD 394 million; Fosun Pharma rose 4.62%, with a transaction volume of HKD 243 million; Heng Rui Medicine rose 0.60%, with a market value of HKD 555.9 billion

    HK Stock Movers Tracker·
    HK
    00950
    -0.59%
    HK Stock Movers Tracker·
    HK
    00950
    -0.59%
    © 2025 Longbridge｜Disclaimer